Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?
Loading...
Issue Date
2019-01
Authors
Crass, Ryan L
Pai, Manjunath P
Lodise, Thomas P
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Background: Empirical models to predict beta-lactam pharmacokinetics (PK) using information from routine aminoglycoside therapeutic drug monitoring (TDM) have been proposed for critically ill patients; however, no such models exist for patients with cystic fibrosis (CF).
Objectives: To investigate whether PK parameters of tobramycin could be used to predict those of piperacillin.
Methods: A non-interventional, open-label PK study was conducted in hospitalized adults treated with piperacillin/tazobactam and tobramycin for acute pulmonary exacerbations of CF. Six serum samples per patient were collected and analysed. One- and two-compartment population PK models with linear, Michaelis-Menten or mixed elimination were evaluated for both drugs within the PmetricsTM package for R. Models were developed and compared iteratively using the log-likelihood and Akaike information criterion (AIC) objective functions.
Results: Nine primarily female (n = 8) and Caucasian (100%) adult CF patients were enrolled. The median (IQR) age, height, weight and serum creatinine of included patients was 31 (27-32) years, 51.4 (49.9-55.8) kg, 162.6 (160.0-165.1) cm and 0.6 (0.5-0.6) mg/dL, respectively. The final model with the lowest objective function values consisted of one compartment with first-order elimination for tobramycin and two compartments with mixed-order elimination for piperacillin with the elimination rate constant of piperacillin modelled as a linear function of the elimination rate constant of tobramycin.
Conclusions: A relationship was identified between the elimination rate constants of tobramycin and piperacillin. Validation of this relationship in larger studies of adult patients with CF is needed before application to the precision dosing of piperacillin/tazobactam in this patient population.
Citation
Crass RL, Pai MP, Lodise TP Jr. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help? J Antimicrob Chemother. 2019 Jan 1;74(1):126-129. doi: 10.1093/jac/dky388. PMID: 30252050.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).